Prostate-specificmembrane antigen (PSMA) and gastrin-releasingpeptide receptor (GRPR) have been used for diagnostic molecular imaging/therapyof prostate cancer (PCa). This evidence concerns the gene FOLH1 and prostate carcinoma.